Yijia Group Corp. Files Q3 2024 10-Q

TL;DR

Yijia Group Corp. filed their Q3 10-Q for Oct 2024. Check financials.

AI Summary

Yijia Group Corp. filed a 10-Q for the period ending October 31, 2024. The filing covers the third quarter of their fiscal year, which began on August 1, 2024, and ended on October 31, 2024. The company's fiscal year ends on April 30th. Their business address is located at 39 E. Broadway, Suite 603, New York, NY 10002.

Why It Matters

This filing provides investors with an update on Yijia Group Corp.'s financial performance and operational status for the third quarter of fiscal year 2024.

Risk Assessment

Risk Level: low — The filing is a standard quarterly report with no immediate red flags or significant negative events indicated.

Key Numbers

• 2024-10-31 — Fiscal Period End Date (Reporting period for the 10-Q filing.)
• 2024-12-13 — Filing Date (Date the 10-Q was submitted to the SEC.)
• 0430 — Fiscal Year End (Indicates the end of Yijia Group Corp.'s fiscal year.)

Key Players & Entities

• YIJIA GROUP CORP. (company) — Filer
• 0001699709 (company) — Central Index Key
• 39 E. BROADWAY, STE 603 (location) — Business Address
• NEW YORK (location) — Business Address City
• 10002 (location) — Business Address Zip
• Soldino Group Corp (company) — Former Company Name

FAQ

Key Financial Figures

• $1 — 100 shares of common stock, par value $1 per share 100 % YJGJ and its subsid
• $0.05 — al Officer - Steve Niu at fair value of $0.05 per share, subject to vesting condition

Filing Documents

• yijia_i10q-103124.htm (10-Q) — 564KB
• yijia_ex3101.htm (EX-31.1) — 9KB
• yijia_ex3102.htm (EX-31.2) — 9KB
• yijia_ex3201.htm (EX-32.1) — 4KB
• 0001683168-24-008711.txt ( ) — 3260KB
• yjgj-20241031.xsd (EX-101.SCH) — 26KB
• yjgj-20241031_cal.xml (EX-101.CAL) — 36KB
• yjgj-20241031_def.xml (EX-101.DEF) — 67KB
• yjgj-20241031_lab.xml (EX-101.LAB) — 217KB
• yjgj-20241031_pre.xml (EX-101.PRE) — 179KB
• yijia_i10q-103124_htm.xml (XML) — 469KB

Financial Statements

Financial Statements 3 Unaudited Condensed Consolidated Balance Sheets as of October 31, 2024 and April 30, 2024 4 Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months ended October 31, 2024 and 2023 5 Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) for the Six Months Ended October 31, 2024 and 2023 6 Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months ended October 31, 2024 and 2023 7 Notes to the Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23 PART II OTHER INFORMATION: Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 25

Signatures

Signatures 2 PART 1 – FINANCIAL INFORMATION Item 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS The accompanying interim consolidated financial without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with United States generally accepted principles have been condensed or omitted pursuant to such rules and regulations. The interim consolidated financial statements are condensed and should be read in conjunction with the Company's latest annual consolidated financial statements. In the opinion of management, the consolidated financial statements contain all material adjustments, consisting only of normal adjustments considered necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented. 3 YIJIA GROUP CORP. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS October 31, 2024 April 30, 2024 (Unaudited) ASSETS Current assets: Cash $ 222,795 $ 593,036 Accounts receivable 57,700 – Advances to vendors 671,782 460,870 Inventories 303,094 132,873 Other current assets 3,441 6,079 Total current assets 1,258,812 1,192,858 TOTAL ASSETS $ 1,258,812 $ 1,192,858 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current Liabilities: Accounts payable and accrued expenses $ 69,375 $ 60,749 Other current liabilities 902 8,302 Amounts due to a related party 128,000 3,000 Income tax payable 25,661 64,869 Total current liabilities 223,938 136,920 TOTAL LIABILITIES 223,938 136,920 Commitments and Contingencies – – Shareholders' equity: Ordinary shares, $ 0.001 par value; 75,000,000 shares authorized; 25,012,270 shares issued and outstanding as of October 31 and April 30, 2024 25,012 25,012 Additional paid in capital 1,012,971 1,012,971 Shares to be issued – 3

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS NOTE 1 – ORGANIZATION AND NATURE OF

BUSINESS

BUSINESS Yijia Group Corp. ("the Company" or "YJGJ") was incorporated on January 25, 2017 under the laws of the State of Nevada, United States of America, formerly known as Soldino Group Corp. The Company has currently commenced its operation in the rendering of consulting advisory services in management business, accounting and finance services; and provides healthcare products and health consultation services to domestic and international customers. The details of the Company's subsidiary are described below: Schedule of details of company subsidiary Name Place of incorporation and kind of legal entity Principal activities and place of operation Particulars of issued/ registered share capital Effective interest Held Nutripeak Trading Corporation ("NTC") Marketing and supplying healthcare products 100 shares of common stock, par value $1 per share 100 % YJGJ and its subsidiary are hereinafter referred to as (the "Company"). NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by management in accordance with both accounting principles generally accepted in the United States ("GAAP"), and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and note disclosures normally included in audited consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. The unaudited condensed consolidated financial statements are presented in US dollars, which is the Company's functional currency. In the opinion of management, the condensed balance sheet as of April 30, 2024 which has been derived from audited consolidated financial statem

financial statements and accompanying notes. Actual results could differ from those estimates

financial statements and accompanying notes. Actual results could differ from those estimates. Significant areas for which management uses estimates include: sales returns at point in time and allowances; inventory; income tax valuation allowances These estimates require the use of judgment as future events, and the effect of these events cannot be predicted with certainty. The estimates will change as new events occur, as more experience is acquired and as more information is obtained. We evaluate and update our assumptions and estimates on an ongoing basis and we may consult outside experts to assist as considered necessary. Revenue Recognition identify the contract with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to performance obligations in the contract; and recognize revenue as the performance obligation is satisfied. Currently, the Company operates in two business segments. The Consulting Service Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. Revenue is recognized from the sale of their healthcare products upon delivery to the customers, whereas the title and risk of loss are fully transferred to customers. 9 Shipping term under Ex Works ("EXW"), the Company fulfills the obligation to deliver when the products are available on their premises, i.e. the warehouse. Customers are responsible for all transportation costs, risk of loss, and any other costs that point onward. Revenue is earned from the rendering of consulting advisory services to customers. The Company recognizes services revenue over the period in which such services a

View Full Filing

View this 10-Q filing on SEC EDGAR